SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 (Suciraslimab) is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and has completed Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Thirteenth Five-Year Plan Period. SM03 has met its primary endpoint in its Phase III clinical study for the treatment of rheumatoid arthritis (RA) in China in April 2023. On 5 September 2023, the National Medical Products Administration of the People's Republic of China has accepted the biologics license application (BLA) for SM03 (Suciraslimab) in the treatment of RA.
Humanized monoclonal antibody targeting the receptor for IL-25
First-in-Class and First-in-Target